Be part of the knowledge.™

Oncology and Hematology

1923

LikeLikedUnlike

Episodes 16-30 of 258

Molecular Profiling for HER2+ Advanced Solid Tumors
CME/CE
Molecular Profiling for HER2+ Advanced Solid Tumors
- Eric Van Cutsem, MD, PhD
  Peer
- David SP Tan, MBBS, PhD, PRCP
  Peer
- James Chih-Hsin Yang, MD, PhD
  Peer
- Kathleen Moore, MD, MS, FASCO
  Peer
1.00 credits
Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor
MinuteCE®
Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor
- Seema A. Bhat, MD
  Peer
- Jeremy S. Abramson, MD, MMSc
  Peer
0.50 program credits
Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies
MinuteCE®
Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies
- Seema A. Bhat, MD
  Peer
- Jeremy S. Abramson, MD, MMSc
  Peer
0.50 program credits
Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy
MinuteCE®
Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy
- Seema A. Bhat, MD
  Peer
- Jeremy S. Abramson, MD, MMSc
  Peer
0.50 program credits
Emerging data with potentially guideline-changing implications in CLL/SLL and MCL
MinuteCE®
Emerging data with potentially guideline-changing implications in CLL/SLL and MCL
- Seema A. Bhat, MD
  Peer
- Jeremy S. Abramson, MD, MMSc
  Peer
0.50 program credits
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
CME/CE
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
- Jeffrey V. Matous, MD
  Peer
- Donna Catamero, NP
  Peer
0.25 credits
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
CME/CE
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
- Jorge E. Cortes, MD
  Peer
0.25 credits
MinuteCE®
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC): From Diagnosis to Treatment
- Efrat Dotan, MD
  Peer
- Shubham Pant, MD, MBBS
  Peer
0.25 credits 2 episodes
Diagnosis and Management of Metastatic PDAC
MinuteCE®
Diagnosis and Management of Metastatic PDAC
- Efrat Dotan, MD
  Peer
- Shubham Pant, MD, MBBS
  Peer
0.25 program credits
Chemotherapy Strategies for Metastatic PDAC
MinuteCE®
Chemotherapy Strategies for Metastatic PDAC
- Efrat Dotan, MD
  Peer
- Shubham Pant, MD, MBBS
  Peer
0.25 program credits
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
CME/CE
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
- Jonathan Leventhal, MD
  Peer
- Shahnaz Singh-Kandah, NP
  Peer
0.25 credits
MinuteCE®
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
- William J. Gradishar, MD
  Peer
- Erica L. Mayer, MD, MPH
  Peer
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 credits 10 episodes
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
- Sara Lonardi, MD
  Peer
- Aparna R. Parikh, MD
  Peer
- Alan Venook, MD
  Peer
1.25 credits 10 episodes
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
- Erica L. Mayer, MD, MPH
  Peer
1.50 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended